Melanoma Matters22 Des 2025

Ep 74: Best of ESMO 2025: Part 2 of 2

Summary

In this Part 2 Best of ESMO 2025 episode of Melanoma Matters, hosts James Larkin and Sapna Patel cover the IO Biotech phase 3 trial, Checkmate 238 final results, the Safe Stop trial, the ECOG-ACRIN STAMP trial for Merkel cell carcinoma, and a promising TCR therapy for uveal melanoma.

Keywords

melanoma, cancer research, immunotherapy, clinical trials, ESMO, IO Biotech, Checkmate 238, Safe Stop trial, STAMP trial, uveal melanoma

Takeaways

The IO Biotech trial missed its primary endpoint for PFS.

Checkmate 238 confirmed previous findings on RFS and DMFS.

The Safe Stop trial suggests early discontinuation of therapy may be safe.

STAMP trial shows potential for adjuvant pembrolizumab in Merkel cell carcinoma.

Uveal melanoma TCR therapy shows promise.

Understanding subgroup analysis in interpreting trial results.

Patient management decisions should consider trial limitations and real-world implications.

Chapters

00:00 Travel Tips and Strategies

04:43 IO Biotech Phase 3 Trial Insights

12:00 Checkmate 238 Discussion

13:10 Navigating Publication Challenges

13:59 Checkmate 238 Results

15:58 Late Relapses and Follow-Up Strategies

17:57 Time of Day of Infusion

20:50 Safe Stop Trial: Evaluating Treatment Duration

33:12 STAMP Trial: Adjuvant Therapy for Merkel Cell Carcinoma

35:05 IMA-203 (Anzu-cel) trial in uveal melanoma

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(95)

Preview of a PREVIEW

ADCs are coming in melanoma and James is stunned into silence for 45s

16 Okt 1min

Ep 89: PREVIEW ESMO Annual Meeting: 2026 Madrid

James and Sapna discuss all the meanings of the word "pike" and preview the presentations they are looking forward to at the 2026 ESMO Annual Congress from the Melanoma and Skin Tumours track. Sapna w...

16 Okt 15min

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Sep 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Aug 10s

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Aug 12min

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Aug 52min

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Jul 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Jul 35min